E
Emily M. Hawes
Researcher at University of North Carolina at Chapel Hill
Publications - 44
Citations - 994
Emily M. Hawes is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Rivaroxaban & Health care. The author has an hindex of 14, co-authored 38 publications receiving 841 citations. Previous affiliations of Emily M. Hawes include UNC Health Care.
Papers
More filters
Journal ArticleDOI
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Emily M. Hawes,Allison M. Deal,D. Funk-Adcock,Robert C. Gosselin,C. Jeanneret,A. M. Cook,J. M. Taylor,Herbert C. Whinna,A. M. Winkler,Stephan Moll +9 more
TL;DR: Knowledge of anticoagulation status during dabigatran therapy may be desirable in certain clinical situations.
Journal ArticleDOI
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban
Suzanne J. Francart,Emily M. Hawes,Allison M. Deal,Dorothy M. Adcock,Robert C. Gosselin,Cheryl Jeanneret,Kenneth D. Friedman,Stephan Moll +7 more
TL;DR: PT, aPTT and ACT are often normal in patients on therapeutic doses of rivaroxaban, however, PT and ACT may have clinical utility at higher drug plasma levels.
Journal ArticleDOI
Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update
TL;DR: Key components in the management of ACS include coronary revascularization when indicated; prompt initiation of dual antiplatelet therapy and anticoagulation; and consideration of adjuvant agents including β blockers, inhibitors of the renin angiotensin system, and HmG–coenzyme A reductase inhibitors.
Journal ArticleDOI
Impact of an Outpatient Pharmacist Intervention on Medication Discrepancies and Health Care Resource Utilization in Posthospitalization Care Transitions
TL;DR: A pharmacist-driven intervention focused on patient education and medication reconciliation after discharge improved medication use and reduced health care resource utilization in this pilot study.
Journal ArticleDOI
Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban Can This Test Be Used to Quantify Drug Level?
Robert C. Gosselin,Suzanne J. Francart,Emily M. Hawes,Stephan Moll,William E. Dager,Dorothy M. Adcock +5 more
TL;DR: A strong correlation, but variability between kits, is demonstrated for assessing rivaroxaban concentrations using heparin anti–factor Xa assays, which may be useful only for trough samples.